Trametinib and dabrafenib induced rhabdomyolysis, renal failure, and visual loss. Report of one case.

Author: FinstererJosef

Paper Details 
Original Abstract of the Article :
MEK- and BRAF-inhibitors trametinib and dabrafenib are successfully used for BRAF-mutated, metastasizing melanoma, but these compounds may induce side effects. We report a 50 years old female with BRAF-mutated metastasizing melanoma who received trametinib (2 mg/d) and dabrafenib (200 mg/d) after us...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.4067/S0034-98872020001101684

データ提供:米国国立医学図書館(NLM)

Trametinib and Dabrafenib: A Camel's Cautionary Tale of Drug Side Effects

The world of [Cancer Treatment] is often a balancing act, seeking to maximize benefits while minimizing potential side effects. This case report highlights the possible side effects of [Trametinib] and [Dabrafenib], two drugs used to treat [BRAF-mutated Metastasizing Melanoma]. It's like encountering a treacherous sandstorm in the desert, reminding us that even promising treatments can have unforeseen consequences.

Navigating the Sandstorm: A Camel's Perspective on Drug Side Effects

The researchers describe the case of a patient who experienced a range of adverse effects after starting treatment with trametinib and dabrafenib, including [visual loss], [rhabdomyolysis], and [renal failure]. This serves as a cautionary tale, reminding us that even the most advanced treatments can have unexpected side effects. It’s like navigating a desert where the seemingly benign landscape can suddenly turn dangerous.

A Reminder of Prudence: A Camel's Advice for Drug Therapy

This case report underscores the importance of careful monitoring and early intervention when patients are on targeted therapies. By understanding the potential risks associated with new drugs, we can better manage these challenges and provide patients with the best possible care. It’s like carrying extra water and supplies when traversing a treacherous desert, ensuring that we are prepared for any unexpected events.

Dr. Camel's Conclusion

While targeted therapies have revolutionized cancer treatment, it's crucial to remember that they are not without risks. By carefully navigating the desert of drug therapy, recognizing potential side effects, and taking appropriate precautions, we can help patients achieve optimal outcomes while minimizing potential risks. It's a reminder that even in the most promising of journeys, there are still challenges to be faced, and knowledge and vigilance are our most valuable tools.

Date :
  1. Date Completed 2021-04-14
  2. Date Revised 2021-04-14
Further Info :

Pubmed ID

33844777

DOI: Digital Object Identifier

10.4067/S0034-98872020001101684

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.